An advisory panel of the US Centers for Disease Control and Prevention (CDC) on Thursday decided not to recommend boosters for younger adults, including healthcare workers, who live or work in institutions with high risk of contracting COVID-19, Reuters news agency reported on Friday.
The panel has only recommended a booster shot of the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions that put them at risk of severe disease.
For now, the panel has rejected additional doses for groups including healthcare workers, teachers and residents of homeless shelters and prisons, in part because of the difficulty of implementing such a proposal.
In addition to older Americans, the committee also recommended the booster shots for all adults over 50 with underlying conditions, as well as some 18- to 49-year-olds with those conditions, based on their individual risk profile. Those conditions include cancer, diabetes, certain heart conditions and chronic kidney disease and lung disorders.
The recommendations only cover people who received their second Pfizer/BioNTech shot at least six months earlier. This group is currently about 26 million people, including 13 million aged 65 or older, the CDC said.
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
LakeShore Biopharma receives Nasdaq delisting determination letter
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
GC Biopharma files IND for Phase 3 trial of BARYCELA in Thailand
Novavax COVID-19 vaccine approved in US
WHO and UNICEF deploy PharmaJet's Tropis ID system in Afghanistan polio campaign
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial